Ignacio J. Amat(@ignamatsant) 's Twitter Profileg
Ignacio J. Amat

@ignamatsant

Chief, interventional Cardiologist in HCU Valladolid & H Campogrande

ID:3668130197

linkhttp://www.icicor.es calendar_today15-09-2015 21:57:02

1,6K Tweet

4,2K Takipçi

836 Takip Edilen

Ignacio J. Amat(@ignamatsant) 's Twitter Profile Photo

EL CURSO de shock cardiogenico

Descarga app Eventool para inscripción (viaje/hotel/inscripción gratuitas!): apps.apple.com/es/app/eventoo…
👉únete a
👉concurso de casos
👉talleres hands-on: Mitral, tricúspide, aórtico, ECMO, Impella, pulsecath, flowtriever, penumbra… y +!

account_circle
Ignacio J. Amat(@ignamatsant) 's Twitter Profile Photo

Sapien 3 Ultra Resilia: Critical reflections on Real-World performance

👉Read our Editorial in JACC Journals

authors.elsevier.com/a/1izXK6uPJvuU…

Sapien 3 Ultra Resilia: Critical reflections on Real-World performance 👉Read our Editorial in @JACCJournals authors.elsevier.com/a/1izXK6uPJvuU…
account_circle
Ignacio J. Amat(@ignamatsant) 's Twitter Profile Photo

EL CURSO de shock cardiogenico

Descarga app Eventool para inscripción (viaje/hotel/inscripción gratuitas!): apps.apple.com/es/app/eventoo…
👉únete a
👉concurso de casos
👉talleres hands-on: Mitral, tricúspide, aórtico, ECMO, Impella, pulsecath, flowtriever, penumbra… y +!

account_circle
JAHA(@JAHA_AHA) 's Twitter Profile Photo

Study finds 54% 1-year mortality for patients needing renal therapy post-TAVR. Key predictors include advanced CKD, anemia, diabetes, and nonfemoral access. TRITAVI scores can support prevention. Italo Porto Francesco Saia Ignacio J. Amat ahajournals.org/doi/10.1161/JA…

Study finds 54% 1-year mortality for patients needing renal therapy post-TAVR. Key predictors include advanced CKD, anemia, diabetes, and nonfemoral access. TRITAVI scores can support prevention. #AHAJournals @ItaloPorto2 @saia_francesco @ignamatsant ahajournals.org/doi/10.1161/JA…
account_circle
Ignacio J. Amat(@ignamatsant) 's Twitter Profile Photo

Descarga la app Eventool para inscripción (viaje/hotel/inscripción gratuitas!): apps.apple.com/es/app/eventoo…

👉únete a
👉concurso de casos
👉talleres hands-on: Mitral, tricúspide, aórtico, ECMO, Impella, pulsecath, flowtriever, penumbra… y más‼️

account_circle
Copernican Trial(@CopernicanTrial) 's Twitter Profile Photo

It is a great pleasure to announce the enrollment of the first paciente in the COPERNICAN TRIAL

🔑Objective: Evaluate the role of DCB in STEMI
📕Design: Non-inferiority RCT
🎯Primary EP: TLF at 12 months
🧑‍🤝‍🧑Sample size: 1272 patients
🌏Location: 16 centers in Spain

It is a great pleasure to announce the enrollment of the first paciente in the COPERNICAN TRIAL 🔑Objective: Evaluate the role of DCB in STEMI 📕Design: Non-inferiority RCT 🎯Primary EP: TLF at 12 months 🧑‍🤝‍🧑Sample size: 1272 patients 🌏Location: 16 centers in Spain
account_circle
NEJM(@NEJM) 's Twitter Profile Photo

Presented today at :

In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

Presented today at #ACC24: In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t
account_circle
Medis Imaging(@MedisImaging) 's Twitter Profile Photo

Save the date (09-04-2024): exploring Medis QFR® in the context of acute coronary syndrome (ACS)! 📅

Get ready for the next Medis QFR® Academy session.

Register now: events.teams.microsoft.com/event/aa844f90…
.
.
.
Ignacio J. Amat

Save the date (09-04-2024): exploring Medis QFR® in the context of acute coronary syndrome (ACS)! 📅 Get ready for the next Medis QFR® Academy session. Register now: events.teams.microsoft.com/event/aa844f90… . . . @ignamatsant
account_circle